Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,297.20
(
0.68%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.10
(
-0.55%
)
Bitcoin
74,112.55
(
0.23%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 151055

Tuesday, 10/23/2012 12:59:26 PM

Tuesday, October 23, 2012 12:59:26 PM

Post# of 257253
After the Bardoxolone debacle, ABT needed to ink some drug deals prior to the ABBV spinoff on 12/31/12 to trumpet to investors that ABBV is more than Humira and the HCV pipeline.

I expect even more ABT dealmaking on the drug side of the company before the ABBV spinoff takes effect.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now